Justine E. Koenigsberg
Investor Relations Contact chez CONCERT PHARMACEUTICALS, INC.
Profil
Justine E.
Koenigsberg is currently the SVP-Corporate Communications & Investor Relations at Concert Pharmaceuticals, Inc. She is also a Member at the National Investor Relations Institute.
In 2023, she will start working as the Vice President-Investor Relations at Kymera Therapeutics, Inc. Previously, Ms. Koenigsberg worked as the Director-Corporate Communications at Transkaryotic Therapies, Inc. She also held the position of Director-Investor & Media Relations at ViaCell, Inc. Additionally, she worked as a Principal at Vertex Pharmaceuticals, Inc.Ms. Koenigsberg completed her undergraduate degree at Northeastern University.
Postes actifs de Justine E. Koenigsberg
Sociétés | Poste | Début |
---|---|---|
CONCERT PHARMACEUTICALS, INC. | Investor Relations Contact | 01/03/2008 |
KYMERA THERAPEUTICS, INC. | Investor Relations Contact | 01/07/2023 |
National Investor Relations Institute
National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Corporate Officer/Principal | - |
Anciens postes connus de Justine E. Koenigsberg
Sociétés | Poste | Fin |
---|---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Public Communications Contact | - |
VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Public Communications Contact | - |
Formation de Justine E. Koenigsberg
Northeastern University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
KYMERA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. | Health Technology |
National Investor Relations Institute
National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Commercial Services |